FDA Approves the AVMAPKI\u2122 FAKZYNJA\u2122 Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutat

• click to rate

  Posted by Two Blokes May 8 - Filed in Stock - 4 views
  
  BOSTON--(BUSINESS WIRE)---- $VSTM #FDA--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the U.S. Food and Drug Administration (FDA) has approved AVMAPKI\u2122 FAKZYNJA\u2122 CO-PACK (avutometinib capsules; defactinib tablets) for the treatment of adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who received prior systemic therapy. AVMAPKI FAKZYNJA CO-PACK is the fi.